verified SJR 1,727 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Springer Nature

workspace_premium Q1 — Molecular Biology lock Subscription

Cancer Gene Therapy

Cancer Gene Therapy is a journal indexed in SJR in Molecular Biology and Molecular Medicine with an H index of 101. It has a price of 3490 €. It has an SJR impact factor of 1,727 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,727.

Cancer Gene Therapy focuses its scope in these topics and keywords: tumor, cancer, rna, breast, virus, targeting, necrosis, induces, gene, cells, ...

ISSN: 0929-1903

Publisher: Springer Nature

Category: Molecular Biology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,727 Q1

H-index 101

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.490 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,727

H-index

101

Docs (year)

162

Docs 3y

428

Total refs

9847

Cites 3y

2291

Citable 3y

415

Cites/Doc 2y

5.01

Ref/Doc

60.78

Immediate OA

3490 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma

Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies

Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer

Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs

Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model

B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity

Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein

Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes

Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors

Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil

Antitumor effects of the combination therapy with TNF-a gene-modified tumor cells and interleukin 12 in a melanoma model in mice

Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells

SHOW MORE ARTICLES

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies

A cancer gene therapy approach through translational control of a suicide gene

Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity

Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas

Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma

Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence

Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth

Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines

Activation of host antitumoral responses by cationic lipid/DNA complexes

A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma

FAQs

Cancer Gene Therapy has an SJR of 1,727 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3490 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Cancer Gene Therapy is 25%.

Cancer Gene Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cancer Gene Therapy?

What is the APC / publication cost?

What is the acceptance rate?